Endovasc

Endovasc Inc. was founded in 1996 as an early-stage drug development company dedicated to developing new cardiovascular and metabolic drug therapies, aiming to deliver and release drugs to predetermined targets in an efficient and controlled manner. Endovasc's primary drug candidates include Angiogenix(TM), Liprostin(TM), PROStent(TM) stent coating technology, biodegradable stents, and other drug-eluting stents.